CorporatePresentation(1177.HK)剖析.PDFVIP

Corporate Presentation (1177.HK) March 2017 Presented by Stephen Tse, Executive Director 1 Corporate Overview Business Profile Share Data  Engaged in the RD, manufacturing and  HKEx Code 1177 marketing of a wide range of modernized Chinese medicines and chemical medicines  Board Lot 4,000 shares  Main therapeutic areas include hepatitis,  Issued Shares 7,412,192,209 (as at 31 December 2016) cardio-cerebral diseases, oncology, diabetes, analgesia and respiratory ailments  Market Cap HK$51.7 billion (as at 13 Mar 2017)  FY End Date 31 December  Major Mr. Tse Ping Shareholder Corporate Awards Recent Developments  CAPITAL Magazine – Chinese Outstanding  Has become a Constituent Stock of of the MSCI Global Enterprise Achievement Prize Standard Indices - MSCI China Index  ForbesAsia – Best under a Billion in 2005  FY16: profit attributable to the Group (before accounted for unrealized fair value gains and losses of equity  Economic Digest – Hong Kong Outstanding investments and financial assets) increased 13.2% to Enterprises 2005 approximately HK$2,006,088  Red Herring Magazine – Red Herring Small Cap 100  FY15: profit attributable to the Group (before accounted  Institutional Inve